Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

INDIANAPOLIS , March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial in